CTOs on the Move

Diaceutics PLC

www.diaceutics.com

 
Diaceutics believe that every patient should get the treatment they deserve. We have worked on every Precision Medicine brought to market and we are trusted by the worlds leading pharmaceutical companies. Find out about DXRX - the Diagnostic Network f...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Connecticut Orthopaedics

Connecticut Orthopaedics is a premier team of orthopaedic doctors, surgeons and health care professionals that keep you moving forward with life. Learn more

Reed'S Pharmacy

Reed'S Pharmacy is a Berkeley Springs, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BCM GROUP

BCM GROUP is a Hamburg, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx`s superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx`s innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions. IntelGenx`s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx`s state-of-the-art manufacturing facility offers full service by providing lab-scale through to pilot- and commercial-scale production.

Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.